VIVES is a multi-sector fund that invests in projects with a positive societal impact
ATB Therapeutics is pioneering a new era in targeted therapies by developing next-generation Antibody-Drug Conjugates (ADCs) to transform cancer treatment. By combining cutting-edge biotechnology with...
Novadip was founded in 2013 as spin-off comany from Université Catholique de Louvain and St. Luc University Hospital, based on the scientific discoveries of professor and founder Dr. Denis Dufrane...
The result of more than 15 years of research in the university laboratories of UCLouvain and multiple collaborations (ELEN department, ICTEAM), the VOCSens spin-off is developing a new concept of...
Georges Caron, past CEO Keemotion:
"VIVES supported us at the beginning of the project when the risk was at its maximum. We needed time to test some hypotheses and confront academic research with the...
Denis Périquet, CEO Tessares:
"VIVES supports real innovation projects, while understanding that those projects need time to grow from the academic research phase to a commercial success. Team...
Issam Doghri, Prof. at UCLouvain and co-founder of e-Xstream engineering:
"I developed a first version of a software (Digimat- for digital materials) and I was thinking about ways to make it...
Trial aims to enroll 12 children at eight sites in EU and US
Phase 3 trial in adult patients also planned for 2026 with focus on limb sparing associated with bone non-union (BNU)
Novadip aims to